COPD diagnosis |
23/43 (54.8%) |
|
|
|
|
|
Respiratory failure |
18/43 (41.9%) |
|
|
|
|
|
Asthma |
8/43 (18.6%) |
|
|
|
|
|
Bronchiectasis |
13/43 (30.2%) |
|
|
|
|
|
Interstitial lung disease |
2/43 (4.7%) |
|
|
|
|
|
Silicosis |
1/43 (2.3%) |
|
|
|
|
|
OSA |
16/43 (37.2%) |
|
|
|
|
|
Emphysema |
17/43 (39.5%) |
|
|
|
|
|
Chronic heart disease |
18/43 (41.9%) |
|
|
|
|
|
Arterial hypertension |
19/43 (44.2%) |
|
|
|
|
|
Diabetes |
7/43 (16.3%) |
|
|
|
|
|
Neoplasia |
14/43 (32.6%) |
|
|
|
|
|
Chronic hepatitis B |
1/43 (2.3%) |
|
|
|
|
|
Chronic hepatitis C |
4/43 (9.3%) |
|
|
|
|
|
Lung surgery |
|
|
|
|
|
|
Therapeutic pneumothorax |
6/43 (14.0%) |
|
|
|
|
|
Other lung surgical procedures |
3/43 (7.0%) |
|
|
|
|
|
Patients with airflow obstruction (n=29) |
Nonsmokers (n=6) |
Smokers (n=23) |
p-value |
|
|
|
呼吸功能 |
|
|
|
|
|
|
FEV1L |
0.8 (0.8–0.9) |
1.1 (0.9–1.6) |
0.03 |
|
|
|
FEV1% |
46.0±11.1 |
48.3±17.2 |
0.73 |
|
|
|
FVC L |
1.7±0.8 |
2.7±0.9 |
0.004 |
|
|
|
FVC % |
69.2±15.1 |
78.5±18.6 |
0.20 |
|
|
|
FEV1/FVC |
52.1±12.7 |
45.5±12.7 |
0.21 |
|
|
|
RV % |
165.6±37.0 |
142.7±37.7 |
0.17 |
|
|
|
DLCO% |
|
60.8±22.4 |
|
|
|
|
6MWT |
|
|
|
|
|
|
Distance covered m |
364.1±144.1 |
375.1±121.5 |
0.83 |
|
|
|
Distance % predicted |
81.7±31.4 |
81.5±24.4 |
0.99 |
|
|
|
SpO2baseline |
94.0±1.1 |
94.2±1.6 |
0.74 |
|
|
|
SpO2average |
90.6±3.9 |
89.3±3.8 |
0.40 |
|
|
|
SpO2min |
87.8±5.5 |
86.3±5.1 |
0.47 |
|
|
|
Pulmonary function |
Patients with impaired respiratory pattern#(n=34) |
Patients with normal respiratory pattern (n=9) |
|
Pre-pulmonary rehabilitation |
Post-pulmonary rehabilitation |
p-value |
Pre-pulmonary rehabilitation |
Post-pulmonary rehabilitation |
p-value |
Lung function tests |
|
|
|
|
|
|
FEV1L |
1 (0.8–1.3) |
1.1 (0.9–1.4) |
<0.0001 |
2.3 (1.9–2.6) |
2.5 (1.9–2.9) |
0.21 |
FEV1% |
48.3 (38.3–59.6) |
53.4 (44.0–65.0) |
<0.0001 |
85.2 (81.0–95.4) |
98.1 (85.7–105.6) |
0.21 |
FVC L |
2.3±0.9 |
2.4±0.9 |
0.09 |
2.5±0.7 |
2.8±0.8 |
0.08 |
FVC % |
73.7±17.7 |
78.8±16.9 |
0.003 |
94.6±16.7 |
89.5±37.3 |
0.70 |
FEV1/FVC |
51.4±15.1 |
52.4±14.8 |
0.23 |
77.6±6.2 |
81.1±13.8 |
0.41 |
RV % |
137.1 (111.9–178.9) |
147 (106.3–173.6) |
0.24 |
113.9 (92.7–132.6) |
106.9 (100.8–124.8) |
1.0 |
DLCO% |
60.1±20.5 |
|
|
|
|
|
BGA |
|
|
|
|
|
|
PaO2 |
66.2±7.3 |
70.9±7.2 |
0.009 |
66.3±5.4 |
84.9±0.8 |
0.12 |
PaCO2 |
41.6±6.4 |
39.9±6.0 |
0.10 |
39.6±1.0 |
34.6±2.8 |
0.16 |
PH |
7.4±0.0 |
7.4±0.0 |
0.80 |
7.5±0.0 |
7.4±0.0 |
0.03 |
SaO2 |
94.3 (92.8–95.5) |
95.1 (93.1 - -96.2) |
0.01 |
95.5 (94.1–96.2) |
96.8 (96.7–96.8) |
0.18 |
FIO2 |
21 (21–21) |
21 (21–21) |
0.32 |
|
|
|
6MWT |
|
|
|
|
|
|
Distance covered m |
371±127.5 |
406±133.5 |
0.01 |
407±82.2 |
466±62.5 |
0.05 |
Distance % predicted |
82.1±27.5 |
89.7±28.3 |
0.01 |
86.0±20.3 |
98.4±19.2 |
0.05 |
HR baseline |
80.3±9.9 |
81.9±13.6 |
0.43 |
75.0±10.2 |
78.9±9.1 |
0.40 |
HR average |
102.1±12.6 |
105.9±13.0 |
0.03 |
100.4±7.4 |
100.5±10.2 |
0.97 |
HR max |
112.9±14.5 |
116.7±14.5 |
0.08 |
111.5±11.9 |
111.6±15.1 |
0.98 |
SpO2baseline |
94.3±1.7 |
94.8±1.7 |
0.10 |
95.8±0.9 |
95.9±1.0 |
0.81 |
SpO2average |
90 (87–94) |
91.5 (88.5–94.5) |
0.05 |
95 (94–96) |
96 (94.5–96.0) |
1.0 |
SpO2min |
88 (83–91) |
89 (86.0–92.5) |
0.05 |
94 (93–95) |
94 (92–95) |
0.89 |
Modified Borg dyspnoea baseline |
0 (0–2) |
0 (0–1) |
0.79 |
0 (0–1) |
0 (0–2) |
0.68 |
Modified Borg dyspnoea final |
4 (2–5) |
3 (0.5–4.0) |
0.006 |
4 (1–5) |
2.5 (1.5–4.5) |
0.14 |
Modified Borg fatigue baseline |
0 (0–1) |
0 (0.0–0.8) |
0.77 |
0.5 (0–2) |
0.8 (0.0–1.5) |
0.94 |
Modified Borg fatigue final |
3 (2–5) |
2.5 (0 - 4) |
0.009 |
1 (0–7) |
4 (0.5–4.5) |
0.77 |
Spontaneous walkingSpO2 |
|
|
|
|
|
|
InitialFIO2 |
21 (21–32) |
26日(21 - 30) |
0.40 |
|
|
|
SpO2baseline |
93.2±1.3 |
95.2±1.3 |
0.10 |
|
|
|
SpO2average |
89.5 (88.7–91.5) |
91.5 (90.7–93.2) |
0.04 |
|
|
|
SpO2min |
86 (84–89) |
89 (87–90) |
0.03 |
|
|
|